If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...
6d
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...
Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...
EPS estimates have risen 2.6% over the past 60 days, though revenue expectations have remained essentially flat over the same period. Eight analysts rate the stock a Buy, with a mean price target of ...
Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. SALT LAKE CITY, May ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Beijing Zhongke Journal Publising Co. Ltd. The lead author Cheng-Zhi Qin, a professor of geographical information science (GIS) at Institute of Geographic Sciences and Natural Resources Research, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results